A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of JY09 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin
Phase 3 open-label trial comparing two doses of JY09 versus dulaglutide as add-on therapy to metformin in adults with type 2 diabetes. Enrolled 600 participants with HbA1c as primary endpoint, expected completion October 2026. Beijing Dongfang Biotech is testing a GLP-1 candidate in a crowded T2D market dominated by established players like Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide). This represents another Chinese biotech attempting to challenge Western incumbents in the lucrative diabetes space.